Dr. Monica E. Loghin, MD

Dr. Loghin practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Loghin's NPI, 1750477378, was assigned on October 4, 2006. Dr. Loghin graduated from University of Medicine and Pharmacy ‘Gr T Popa” Iasi in 1983. Dr. Loghin holds Texas license M3006.

Dr. Loghin's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Loghin's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. Dr. Loghin is also affiliated with Houston Methodist Clear Lake Hospital. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Loghin practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Loghin's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Loghin is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Loghin's licenses on file in 10 states: Texas, Florida, Arizona, Mississippi, Tennessee, Washington, Alabama, Georgia, Louisiana and Oklahoma.

Dmand AI lists acute mini-stroke (TIA), epilepsy, essential tremor, fibromyalgia and chronic pain, lower back pain, migraine and chronic headache, muscle weakness and neuropathy among the conditions Dr. Loghin treats.

CMS data shows 353 Medicare services from Dr. Loghin across 5 procedure codes in 2024, for 268 Medicare patients. Medicare paid $35,975 for them.

CMS counts 268 Medicare patients who saw Dr. Loghin in 2024. The largest group is 65 to 74, with 138 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Loghin's median patient age at 68, with 55% women.

In 2024, Dr. Loghin wrote 206 Medicare Part D claims for 72 patients. 91% of them were for generic drugs. CMS names the drug for 77 of them, across 4 drugs with 11 or more claims each, at $2,807 in total drug cost. In 2023, CMS named 98 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Loghin for performance year 2024, reported as part of a group. Dr. Loghin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Loghin as offering telehealth.

Dmand AI links 35 papers to Dr. Loghin, published from 2011 to 2025. 2014 was the busiest year, with 6. The most frequent topics are Brain Neoplasms, Glioblastoma and Antibodies, Monoclonal, Humanized. Dr. Loghin has published most often in J Neurooncol. Dr. Loghin's most frequent co-authors are Barbara Jane O'Brien, MD, Vinay K. Puduvalli, MD and Mark R. Gilbert, MD.

Dmand AI links Dr. Loghin to 1 clinical trial. Conditions studied include Glioblastoma and Astrocytoma.

CMS Open Payments shows 3 general payments to Dr. Loghin from 2 drug and device companies from 2016 to 2018. Food and beverage make up the largest share, 100% of the total. Eisai Inc. paid the most, $23.

Dr. Loghin graduated from University of Medicine and Pharmacy ‘Gr T Popa” Iasi in 1983.

Dr. Loghin is in network with 5 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.